L’Oreal’s CEO confirmed that GLP-1 weight loss drugs are significantly affecting beauty and skincare sales, as the company develops products to address side effects like skin sagging from rapid weight loss.
L’Oreal’s chief executive, described the surge in GLP-1 weight loss drugs as a very important phenomenon for us,
acknowledging their impact on consumer behavior in beauty and skincare categories. The company, which owns brands like SkinCeuticals and Kiehl’s, has launched products designed to counteract side effects of rapid weight loss, such as facial skin sagging, according to a report by the BBC.
GLP-1 Drugs Reshaping Beauty Industry
The rise of GLP-1 medications, including Ozempic and Wegovy, has shifted consumer demand for beauty products. These drugs, originally developed for diabetes, have gained popularity for their weight-loss effects. Rapid weight loss can cause skin elasticity issues. L’Oreal’s CEO emphasized that the trend is not a passing development but a significant commercial variable,
prompting the company to adapt its product strategies.
Hieronimus highlighted that the company’s brands are designed to work alongside and complement GLP-1 and its side effects on skin sagging.
This includes collaborations with dermatology firm Galderma, where L’Oreal increased its stake to 20% last December. Galderma, known for products like Sculptra and Restylane, has also conducted research on the effects of GLP-1 use on facial appearance, as reported by the BBC.
Clinical Aesthetics Partnerships Expand
L’Oreal’s focus on clinical aesthetics reflects broader industry adjustments. The company's strategic partnership with Galderma demonstrates its commitment to addressing challenges from GLP-1 drug users. Both firms are testing products in clinical trials to tackle concerns like loose skin, according to Reuters. This approach aligns with the growing recognition of GLP-1’s long-term implications for consumer spending in beauty and skincare.
The BBC reported that L’Oreal’s sales for the three months ending September rose 7.7%, exceeding analyst expectations. This growth occurs amid a global context where the beauty market is proving resilient. Shifting consumer priorities driven by health trends like GLP-1 adoption influence spending patterns.
GLP-1 Impact Spreading Across Markets
The impact of GLP-1 drugs extends beyond L’Oreal, prompting other consumer brands to factor the trend into their strategic planning. The scale of GLP-1 prescriptions in the U.S. and Europe suggests substantial downstream effects on discretionary spending in beauty categories. L’Orel’s public acknowledgment of this trend positions it among a growing number of companies adapting to evolving consumer needs.